SCHEDULE 13G

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

Aevi Genomic Medicine, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

	00835P105
	(CUSIP Number)

	December 31, 2019
	(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b)

¨ Rule 13d-1(c)

¨ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 10 Pages

CUSIP No. 00835P105

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) Baker Bros. Advisors LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	(a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 564,844 (1)
	6	SHARED VOTING POWER -0-
	7	SOLE DISPOSITIVE POWER 564,844 (1)
	8	SHARED DISPOSITIVE POWER -0-

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 564,844 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.7% (1)(2)
12	TYPE OF REPORTING PERSON (See Instructions) IA, PN

	(1)	Includes 564,844 shares of common stock (“Common Stock”) of Aevi Genomic Medicine, Inc. (the “Issuer”) underlying Warrants (as defined below) that are subject to the limitations on exercise described in Item 4.
	(2)	Based on 77,713,782 shares of Common Stock outstanding as of December 20, 2019, as reported in the Issuer’s Proxy filed with the Securities and Exchange Commission (“SEC”) on December 31, 2019.

Page 2 of 10 Pages

CUSIP No. 00835P105

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) Baker Bros. Advisors (GP) LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	(a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 564,844 (1)
	6	SHARED VOTING POWER -0-
	7	SOLE DISPOSITIVE POWER 564,844 (1)
	8	SHARED DISPOSITIVE POWER -0-

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 564,844 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.7% (1)(2)
12	TYPE OF REPORTING PERSON (See Instructions) HC, OO

(1)

Includes 564,844 shares of Common Stock underlying Warrants (as defined below) that are subject to the limitations on exercise described in Item 4.

(2)

Based on 77,713,782 shares of Common Stock outstanding as of December 20, 2019, as reported in the Issuer’s Proxy filed with the SEC on December 31, 2019.

Page 3 of 10 Pages

CUSIP No. 00835P105

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) Felix J. Baker
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	(a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 564,844 (1)
	6	SHARED VOTING POWER -0-
	7	SOLE DISPOSITIVE POWER 564,844 (1)
	8	SHARED DISPOSITIVE POWER -0-

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 564,844 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.7% (1)(2)
12	TYPE OF REPORTING PERSON (See Instructions) IN, HC

(1)

Includes 564,844 shares of Common Stock underlying Warrants (as defined below) that are subject to the limitations on exercise described in Item 4.

(2)

Based on 77,713,782 shares of Common Stock outstanding as of December 20, 2019, as reported in the Issuer’s Proxy filed with the SEC on December 31, 2019.

Page 4 of 10 Pages

CUSIP No. 00835P105

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) Julian C. Baker
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	(a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 564,844 (1)
	6	SHARED VOTING POWER -0-
	7	SOLE DISPOSITIVE POWER 564,844 (1)
	8	SHARED DISPOSITIVE POWER -0-

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 564,844 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.7% (1)(2)
12	TYPE OF REPORTING PERSON (See Instructions) IN, HC

(1)

Includes 564,844 shares of Common Stock underlying Warrants (as defined below) that are subject to the limitations on exercise described in Item 4.

(2)

Based on 77,713,782 shares of Common Stock outstanding as of December 20, 2019, as reported in the Issuer’s Proxy filed with the SEC on December 31, 2019.

Page 5 of 10 Pages

Amendment No. 2 to Schedule 13G

This Amendment No. 2 to Schedule 13G amends the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

Item 1(a)

Name of Issuer:

Aevi Genomic Medicine, Inc.

Item 1(b)

Address of Issuer’s Principal Executive Offices:

435 Devon Park Drive, Ste. 715

Wayne, Pennsylvania 19087

Item 2(a)

Name of Person Filing:

This Amendment No. 2 is being filed jointly by the Reporting Persons.

Item 2(b)

Address of Principal Business Office or, if None, Residence:

The business address of each of the Reporting Persons is:

c/o Baker Bros. Advisors LP

860 Washington Street, 3^rd Floor

New York, NY 10014

(212) 339-5690

Item 2(c)

Citizenship:

The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

Item 2(d)

Title of Class of Securities

Common Stock, $0.0001 par value per share (“Common Stock”)

Item 2(e)

CUSIP Number

00835P105

Page 6 of 10 Pages

	Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

		(a) ¨ Broker or dealer registered under Section 15 of the Exchange Act.

		(b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act.

		(c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.

		(d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940.

		(e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

		(f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

		(g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

		(h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

		(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.

		(j) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4.

Ownership.

Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 2 are incorporated herein reference. Set forth below is the aggregate number of shares of Common Stock that may be acquired by 667, L.P. and Baker Brothers Life Sciences, L.P. (collectively the “Funds”), upon exercise of warrants at an exercise price of $2.84 per share expiring October 17, 2022 (“2022 Warrants”), subject to the limitation on exercise described below. The information set forth below is based upon 77,713,782 shares of Common Stock outstanding as of December 20, 2019, as reported on the Issuer’s Proxy filed with the SEC on December 31, 2019. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

Page 7 of 10 Pages

Name	Number of Shares of Common Stock we own or have the right to acquire within 60 days		Percent of Class Outstanding
667, L.P.		57,035		0.1	%
Baker Brothers Life Sciences, L.P.		507,809		0.6	%
Total		564,844		0.7	%

The 2022 Warrants are only exercisable to the extent that the holders thereof together with their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding Common Stock of the Issuer after conversion (“Beneficial Ownership Limitation”). As a result of this restriction, the number of shares that may be issued upon exercise of the 2022 Warrants by the above holders may change depending upon changes in the outstanding shares. By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage. Any such increase will not be effective until the 65th day after such notice is delivered to the Issuer.

Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

The information in Item 4 is incorporated herein by reference.

Page 8 of 10 Pages

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

The information in Item 4 is incorporated herein by reference.

Item 8.

Identification and Classification of Members of the Group.

N/A

Item 9.

Notice of Dissolution of Group.

N/A

Item 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 9 of 10 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2020

	BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its general partner

	By:	/s/ Scott L. Lessing
		Name: Scott L. Lessing Title: President

	BAKER BROS. ADVISORS (GP) LLC

	By:	/s/ Scott L. Lessing
		Name: Scott L. Lessing Title: President

	/s/ Julian C. Baker
	Julian C. Baker

	/s/ Felix J. Baker
	Felix J. Baker

Page 10 of 10 Pages

Aevi Genomic Medicine, LLC SC 13G/A